Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer
995.4000 -7.10 (-0.71%)
NSE Jul 02, 2025 15:31 PM
Volume: 1.2M
 

995.40
-0.71%
HDFC Securities
Maintain BUY rating with a TP of Rs 465 (22x Dec-20E EPS). Cadila (CDH) reported a bumper quarter in 3QFY19 with revenue at Rs 35.9bn, up 11/23% YoY/QoQ (12% beat). Seasonality in the US and several launches over the last 6 months were the key reasons. Although EBITDA margin at 24.2% was up 257bps QoQ (155bps miss) on account of higher operating leverage in the US, there was a 300bps drop in gross margin due to higher AG sales.
Zydus Lifesciences L.. has an average target of 1024.00 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended